MECP2 and Neurodevelopmental delay: Thus, the combination of this live-cell imaging tool with newly established cellular models of NDD provides a platform to directly screen and evaluate new therapeutic interventions that can normalize the DNA-binding capacity of pathogenic MeCP2 or other chromatin-associated proteins [249].